Expanding the inhibitor space of the WWP1 and WWP2 HECT E3 ligases
- J Enzyme Inhib Med Chem. 2024 Dec;39(1):2394895. doi: 10.1080/14756366.2024.2394895.
- 1. School of Biological Sciences, University of East Anglia, Norwich, UK.
- 2. School of Chemistry, Pharmacy & Pharmacology, University of East Anglia, Norwich, UK.
- 3. International Research Center for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
The HECT E3 ubiquitin ligases 1 (WWP1) and 2 (WWP2) are responsible for the ubiquitin-mediated degradation of key tumour suppressor proteins and are dysregulated in various cancers and diseases. Here we expand their limited inhibitor space by identification of NSC-217913 displaying a WWP1 IC50 of 158.3 µM (95% CI = 128.7, 195.1 µM). A structure-activity relationship by synthesis approach aided by molecular docking led to compound 11 which displayed increased potency with an IC50 of 32.7 µM (95% CI = 24.6, 44.3 µM) for WWP1 and 269.2 µM (95% CI = 209.4, 347.9 µM) for WWP2. Molecular docking yielded active site-bound poses suggesting that the heterocyclic imidazo[4,5-b]pyrazine scaffold undertakes a π-stacking interaction with the phenolic group of tyrosine, and the ethyl ester enables strong ion-dipole interactions. Given the therapeutic potential of WWP1 and WWP2, we propose that compound 11 may provide a basis for future lead compound development.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: E1/E2/E3 EnzymeResearch Areas: Cancer
-
target: E1/E2/E3 EnzymeResearch Areas: Cancer